PortalPublikationenEarly decline in cancer antigen 125 as a surrogate for progr...

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer

Standard

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. / Lee, Chee K; Friedlander, Michael; Brown, Chris; Gebski, Val J; Georgoulopoulos, Alexander; Vergote, Ignace; Pignata, Sandro; Donadello, Nicoletta; Schmalfeldt, Barbara; Delva, Rémy; Mirza, Mansoor Raza; Sauthier, Philippe; Pujade-Lauraine, Eric; Lord, Sarah J; Simes, R John.

in: JNCI-J NATL CANCER I, Jahrgang 103, Nr. 17, 07.09.2011, S. 1338-42.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lee, CK, Friedlander, M, Brown, C, Gebski, VJ, Georgoulopoulos, A, Vergote, I, Pignata, S, Donadello, N, Schmalfeldt, B, Delva, R, Mirza, MR, Sauthier, P, Pujade-Lauraine, E, Lord, SJ & Simes, RJ 2011, 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer', JNCI-J NATL CANCER I, Jg. 103, Nr. 17, S. 1338-42. https://doi.org/10.1093/jnci/djr282

APA

Lee, C. K., Friedlander, M., Brown, C., Gebski, V. J., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Mirza, M. R., Sauthier, P., Pujade-Lauraine, E., Lord, S. J., & Simes, R. J. (2011). Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. JNCI-J NATL CANCER I, 103(17), 1338-42. https://doi.org/10.1093/jnci/djr282

Vancouver

Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. JNCI-J NATL CANCER I. 2011 Sep 7;103(17):1338-42. https://doi.org/10.1093/jnci/djr282

Bibtex

@article{357d1ee22cdf41cfb76f537cfd161544,
title = "Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer",
abstract = "We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin-paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P = .02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P = .01). However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P < .001) or an early response (146 [33.9%] vs 176 [38.7%], P = .14) compared with CP patients. The PFS for CPLD patients did not change statistically significantly after adjustment for early decline (adjusted HR = 0.80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, CA-125 Antigen, Carboplatin, Confidence Intervals, Disease-Free Survival, Doxorubicin, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Multivariate Analysis, Odds Ratio, Ovarian Neoplasms, Paclitaxel, Polyethylene Glycols, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Recurrence, Reproducibility of Results, Time Factors, Tumor Markers, Biological",
author = "Lee, {Chee K} and Michael Friedlander and Chris Brown and Gebski, {Val J} and Alexander Georgoulopoulos and Ignace Vergote and Sandro Pignata and Nicoletta Donadello and Barbara Schmalfeldt and R{\'e}my Delva and Mirza, {Mansoor Raza} and Philippe Sauthier and Eric Pujade-Lauraine and Lord, {Sarah J} and Simes, {R John}",
year = "2011",
month = sep,
day = "7",
doi = "10.1093/jnci/djr282",
language = "English",
volume = "103",
pages = "1338--42",
journal = "JNCI-J NATL CANCER I",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "17",

}

RIS

TY - JOUR

T1 - Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer

AU - Lee, Chee K

AU - Friedlander, Michael

AU - Brown, Chris

AU - Gebski, Val J

AU - Georgoulopoulos, Alexander

AU - Vergote, Ignace

AU - Pignata, Sandro

AU - Donadello, Nicoletta

AU - Schmalfeldt, Barbara

AU - Delva, Rémy

AU - Mirza, Mansoor Raza

AU - Sauthier, Philippe

AU - Pujade-Lauraine, Eric

AU - Lord, Sarah J

AU - Simes, R John

PY - 2011/9/7

Y1 - 2011/9/7

N2 - We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin-paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P = .02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P = .01). However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P < .001) or an early response (146 [33.9%] vs 176 [38.7%], P = .14) compared with CP patients. The PFS for CPLD patients did not change statistically significantly after adjustment for early decline (adjusted HR = 0.80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit.

AB - We used data from 886 patients from the CAELYX in Platinum Sensitive Ovarian Patients (CALYPSO) trial, recruited between April 2005 and September 2007, to examine the role of early decline in cancer antigen 125 (CA125) and early tumor response as prognostic factors and surrogates for superiority of treatment with carboplatin-pegylated liposomal doxorubicin (CPLD) compared with carboplatin-paclitaxel (CP) in a landmark analysis. Progression-free survival (PFS) was estimated by Kaplan-Meier analyses. We used univariate and multivariable Cox proportional hazards analyses to assess early decline and early response as surrogates for CPLD treatment benefit compared with CP. All statistical tests were two-sided. Early decline (defined as rate of CA125 decrease of at least 50% per month) was associated with improved PFS (adjusted hazard ratio [HR] for progression = 0.81, 95% confidence interval [CI] = 0.67 to 0.97, P = .02) but early response (complete or partial responses) was not. CPLD was associated with improved PFS compared with CP (HR = 0.82, 95% CI = 0.69 to 0.96, P = .01). However, fewer CPLD patients had an early decline (161 [37.4%] vs 233 [51.2%], P < .001) or an early response (146 [33.9%] vs 176 [38.7%], P = .14) compared with CP patients. The PFS for CPLD patients did not change statistically significantly after adjustment for early decline (adjusted HR = 0.80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - CA-125 Antigen

KW - Carboplatin

KW - Confidence Intervals

KW - Disease-Free Survival

KW - Doxorubicin

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Middle Aged

KW - Multivariate Analysis

KW - Odds Ratio

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Polyethylene Glycols

KW - Predictive Value of Tests

KW - Prognosis

KW - Proportional Hazards Models

KW - Recurrence

KW - Reproducibility of Results

KW - Time Factors

KW - Tumor Markers, Biological

U2 - 10.1093/jnci/djr282

DO - 10.1093/jnci/djr282

M3 - SCORING: Journal article

C2 - 21840849

VL - 103

SP - 1338

EP - 1342

JO - JNCI-J NATL CANCER I

JF - JNCI-J NATL CANCER I

SN - 0027-8874

IS - 17

ER -